The discovery of FasL expression by a variety of tumour cells (Bennett et al, 1998; O'Connell et al, 1998; Mann et al, 1999) raised the possibility that FasL may also mediate immune privilege in human tumours. This evidence concerns the gene FASLG and neoplasm.